Robert Lakin

Robert Lakin

InvestorPlace Contributor

A journalist — both writer and editor — Robert has covered markets and economies for more than 20 years. His previous gigs include Bloomberg News, where he was emerging markets editor in Tel Aviv, McKinsey & Co. and McDonald & Company Investments, where he was equities research editor.

His deep experience includes covering startups, emerging markets, financial services, and capital markets.

He writes a Substack newsletter, TLV Strategist, which covers the Israel business scene.

Recent Articles

SSPK Stock: Why Silver Spike Shares Are Surging Ahead of the Weedmaps SPAC Merger

By Robert Lakin, InvestorPlace Contributor

SSPK stock is surging Thursday morning after Silver Spike announced its pending Weedmaps SPAC merger. Here's what you need to know.

PIC Stock: Pivotal Investment Shares Surge Ahead of XL Fleet SPAC Merger

By Robert Lakin, InvestorPlace Contributor

PIC stock is surging Wednesday as investors anticipate the close of the SPAC merger between XL Fleet and Pivotal Investment.

SRNE Stock: California Testing Approval Stokes Sorrento Therapeutics

By Robert Lakin, InvestorPlace Contributor

Sorrento Therapeutics is poised to roll out clinical testing trials in California. SRNE stock is up in pre-market trading on Wednesday as the country continues to post record Covid-19 diagnoses and hospitalizations.

Walgreens CFO Plays Down Impact of Amazon Online Pharmacy

By Robert Lakin, InvestorPlace Contributor

WBA stock has plunged following Amazon's online pharmacy announcement. Walgreen's CFO cautioned on market overreaction.

Buffett’s Berkshire Hathaway Buys New Stakes in Vaccine Makers, Cuts Banks

By Robert Lakin, InvestorPlace Contributor

Warren Buffett is ditching bank stocks and loading up on drug makers, according to Berkshire Hathaway's latest regulatory filing.

Load More